Corcept Therapeutics | CORT - Ebitda


Corcept Therapeutics reported $-49M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
ANI Pharmaceuticals USD 71.6M 6.69M Jun/2026
Ardelyx USD -29.77M 35.79M Mar/2026
Aurora Cannabis CAD 3.7M 14.78M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Canopy Growth CAD -137M 134.13M Mar/2026
Corcept Therapeutics USD -49M 53.2M Mar/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Lexicon Pharmaceuticals USD -12.04M 15.95M Sep/2025
Merck USD -1.54B 7.84B Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Novartis USD 5.41B 431M Mar/2026
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 48.67M 8.43M Jun/2026
Pfizer USD 6.01B 18M Jun/2026
Supernus Pharmaceuticals USD 31.6M 2.37M Jun/2026
TG Therapeutics USD 26.9M 1.21M Jun/2026